Navigation Links
LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
Date:4/30/2008

uding these items, the non-GAAP operating loss for Q1 2008 was $1.5 million. The Q1 2007 GAAP and non-GAAP operating loss was $1.0 million.

The Company reported a net loss of $2.6 million in Q1 2008, or $0.17 per diluted share, compared to a net loss of $0.6 million, or $0.04 per diluted share, for Q1 2007.

Mr. LeMaitre continued, "Partly in response to market conditions, we have recently heightened our focus on the bottom line. The February RIF reduced headcount from 257 at year-end to 218 at March 31, 2008, a level last seen in Q1, 2005. We have also recently undertaken a belt-tightening regime, the 2008 Expense Shave. Based on our continued sales momentum, coupled with these cost-cutting initiatives, I'm confident we will achieve our 2008 top- and bottom-line guidance."

Sales and marketing expenses for Q1 2008 increased 21% to $5.8 million from $4.8 million in 2007. Excluding the effects of the weak dollar, the increase was 15%. The start-up of our French and Italian sales forces added $0.6 million of new expenses in Q1 2008.

For Q1 2008, general and administrative expenses increased 19% to $2.8 million. Excluding the effects of the weak dollar, the G&A increase was 15% and was driven by Biomateriali's inclusion on the income statement.

R&D expenses increased $0.2 million to $1.3 million in Q1 2008. The EndoFit Thoracic Uniform TopStent launch progressed smoothly in Q1. Coupled with the recently-launched TT Introducer, this uniform TopStent is designed to substantially improve deployment accuracy.

The Company ended Q1 2008 with $17.8 million in cash and marketable securities, compared to $22.9 million at December 31, 2007. $4.0 million of this $5.1 million decrease is attributable to the following items: the termination of the Italian distributor relationship ($1.2 million), 2007 annual employee bonuses ($1.1 million), inventory and accounts receivable increases ($0.8 million), acquisition-related payments ($0.7 million),
'/>"/>

SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. LeMaitre Vascular to Participate in 28th Annual Cowen and Company Health Care Conference
2. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
3. LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors
4. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
5. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
6. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
7. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
8. ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
9. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
10. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
11. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th ... will take place at the Congress Center ... is now available at http://www.abim.ch . ... organizations from all over the globe will ... latest products and developments on the world ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and ... and Forecast (2011 - 2016)," analyzes the chocolate ... the major market drivers, restraints, and opportunities for the ... The global chocolate market is expected to grow from ... an estimated CAGR of 2.7% from 2011 to 2016. ...
(Date:10/18/2014)... 2014 The Asia-Pacific Bio-based Advanced ... the bio-based advanced phase change material market in ... Browse through the TOC of the Asia-Pacific Bio-based ... an idea of the in-depth analysis provided. This ... the Asia-Pacific bio-based advanced phase change material market, ...
(Date:10/18/2014)... The Asian Electronic Medical Record (EMR) market report defines ... forecast of revenue. The electronic medical record market in the ... 2018, at a CAGR of 9.4% from 2013 to 2018. ... Record (EMR) market, to get an idea of the in-depth ... of the market in the same region, and is supported ...
Breaking Biology Technology:Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5
... 9 Insmed Inc. (Nasdaq:,INSM), a developer of follow-on ... Therapeutics, will present at the,Collins Stewart Fourth Annual Growth ... in New York., The conference will take place ... Tuesday, July 8 through Thursday, July 10. Insmed,s,presentation will ...
... Inc.,(OTC Bulletin Board: CAGC) ("China Agritech" or "the ... today announced that it,has entered into a contract ... Ezz,Group, a distributor of agricultural and fertilizer products ... Group began working with China Agritech over a ...
... MARINO, Calif., July 9 Epeius Biotechnologies,Corporation today ... by the U.S. Food and Drug Administration (FDA) ... latest approval is the third,clinical indication for which ... the United States. This latest approval for Rexin-G ...
Cached Biology Technology:Insmed to Present at Collins Stewart Fourth Annual Growth Conference 2China Agritech to Export Products to Egypt 2China Agritech to Export Products to Egypt 3FDA Grants Epeius Biotechnologies' Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas 2FDA Grants Epeius Biotechnologies' Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas 3
(Date:10/14/2014)... 14, 2014 – High doses of fish oil supplements, rich ... common type of irregular heartbeat in which the heart can ... of the AFFORD trial led by the Montreal Heart Institute ... of Cardiology on October 7th. , For the trial, ... were randomly assigned to 4 grams of fish oil a ...
(Date:10/14/2014)... international team of researchers, led by the Chinese Academy ... Nature Genetics a brief genomic history of ... the tomato plant. , The C.M. Rick Tomato Genetics ... in this study by providing seed of both cultivated ... which builds on the first tomato genome sequence completed ...
(Date:10/14/2014)... 14 October 2014 – Researchers from Stanford University School ... mechanism used by cells and the activation of muscle ... blocks" and generate energy during times of nutrient deprivation. ... that when this protective mechanism is operational it also ... "Our study reveals that when stem cells emerge from ...
Breaking Biology News(10 mins):Autophagy helps fast track stem cell activation 2
... may trigger a new mass extinction event, where over 50 ... out, warn scientists at the Universities of York and Leeds. ... discovered a close association between Earth climate and extinctions in ... 520 million years almost the entire fossil record available. ...
... that viruses may contribute to cancer by causing excessive death ... with cancerous traits. Viruses may act as forces of natural ... of viruses and leaving behind those cells that have acquired ... and over, cancer can develop say study authors, led by ...
... Jones, a fisheries oceanographer at the Cooperative Institute for Marine ... Rosenstiel School, set out to design a better light trap ... would contribute to the discovery of a new species. But, ... description, his catch turned out to be the answer to ...
Cached Biology News:Fossil record supports evidence of impending mass extinction 2Study proposes new theory of how viruses may contribute to cancer 2New light trap captures larval stage of new species; DNA barcode technology used 2
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... technology, SilenceMag is the most efficient ... and easy to use, SilenceMag is ... designed for siRNA delivery, SilenceMag allows ... doses of siRNA.,SilenceMag formulation gives reliable ...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
Biology Products: